Shots:

• The P-III PACIFIC trial involves assessing Imfinzi vs PBO in 713 patients with unresectable- stage III NSCLC whose disease had not progressed following concurrent platinum-based CRT in 235 centers across 26 countries
• The updated post-hoc analyses demonstrated OS @5yrs. (42.9% vs 33.4%)- m-OS (47.5 vs 29.1mos); at the treatment course of one year patients had not progressed after 5yrs. (33.1% vs 19%) respectively. The results were presented at ASCO 2021
• The therapy is approved for the treatment of ES-SCLC based on the P-III CASPIAN trial in the EU- US- Japan- and other countries globally and approved for previously treated patients with advanced bladder cancer in several countries

  | Ref: Business Wire | Image: Business Standard